Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL
Clinical trial NCT02151903 · TERMINATED
Trial details
- NCT number
- NCT02151903
- Sponsor
- Alopexx Oncology, LLC
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-04
- Primary completion
- 2016-07-11
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.